3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1/2
2
Phase 1
2
Phase NA
1
Phase 3
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
CNS
1
Conditions
Breast Neoplasms
16
Brain Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasms
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor, Adult
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neuroblastoma
1
Multiple Myeloma
1
Medulloblastoma
1
Lung Neoplasms
1
Liposarcoma
1
Interventions
pembrolizumab
44
Nivolumab
29
Gemcitabine
28
Paclitaxel
19
Cisplatin
18
Ipilimumab
15
Carboplatin
14
Cyclophosphamide
13
Capecitabine
12
Dexamethasone
10
Bevacizumab
10
cemiplimab
9
Irinotecan
9
Docetaxel
9
Albumin-Bound Paclitaxel
9
130-nm albumin-bound paclitaxel
9
spartalizumab
8
Pemetrexed
8
Sorafenib
7
Rituximab
7
Cetuximab
7
fludarabine
6
Temozolomide
6
Taxes
6
Radiotherapy
6
Leucovorin
6
Fluorouracil
6
Azacitidine
6
Ascorbic Acid
6
lenvatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms
×
abemaciclib
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT05386108
2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled